MetaCap

Black Diamond Therapeutics (BDTX) vs Coherus Oncology (CHRS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Black Diamond Therapeutics (BDTX) has outperformed Coherus Oncology (CHRS) over the past year, losing 65.5% versus a loss of 68.1%. Over five years, BDTX leads with a -79.3% price change compared with -98.0% for CHRS. Black Diamond Therapeutics is the larger company by market cap ($75.3 million vs $57.1 million), about 1.3 times the size.

Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus 32.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDTX-65.53%CHRS-68.12%
+126%+24%-77%
Nov 21, 20251 yearNov 20, 2026
BDTX-81.55%CHRS-98.00%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDTX versus CHRS key metrics
MetricBDTXCHRS
Share price$1.31$0.3698
Market cap$75.28M$57.15M
1-day change-5.76%-4.47%
YTD return-46.09%-73.96%
1-year return-65.53%-68.12%
5-year return-79.30%-97.99%
EPS (TTM)$-0.77$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$70.00M$42.17M
Revenue growth (YoY)—+59.81%
Net income (latest FY)$22.37M$168.02M
Gross margin—67.24%
Operating margin17.89%-429.51%
Net margin31.95%398.43%
52-week high$3.97$2.62
52-week low$1.31$0.3628
Distance from 52-week high-67.00%-85.86%
Analyst consensusnonestrong_buy
Avg. price target upside+663.36%+1995.73%
Average volume697.70K1.80M
Shares outstanding57.47M154.54M
Employees21144
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus 32.0 cents for Black Diamond Therapeutics.

About Black Diamond Therapeutics

BDTX stock →

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

BDTX vs CHRS FAQ

Which is bigger, Black Diamond Therapeutics or Coherus Oncology?

Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $75.28M compared with $57.15M for Coherus Oncology (CHRS).

Which stock has performed better over the past year, BDTX or CHRS?

BDTX returned -65.53% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.

Are Black Diamond Therapeutics and Coherus Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons